Efficacy of single-dose galcanezumab 240 mg on episodic or refractory chronic cluster headache: prospective, 4-week, real-world evidence from the GRASP study group.

Objective: This prospective real-world study, conducted by the Greek Research Alliance for the Study of Headache and Pain (GRASP), aimed to evaluate the efficacy, tolerability and safety of subcutaneous galcanezumab 240 mg in reducing the frequency and clinical burden of CH attacks at week 4. Methods: The primary endpoint was the change in the mean number of daily cluster attacks from baseline to weeks 2 and 4. The co-primary endpoint was the ≥50% response rate at week 4 versus baseline. Secondary endpoints included attack duration, pain intensity (VAS 0-10), quality of life (EQ-VAS), treatment satisfaction (PGIC 1-7), and galcanezumab safety and tolerability, all assessed comparing the outcomes at weeks 2 and 4 with those at the baseline. Results: Forty-seven patients with episodic (eCH, Conclusion: A single 240 mg dose of galcanezumab significantly reduced attack frequency, pain, and duration in both patients with eCH and refractory cCH, improved quality of life and patients' satisfaction, and was well-tolerated. These real-world findings support the use of galcanezumab mostly in eCH, while larger studies are needed to clarify its role in cCH.